Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
7.29 USD +10.12% Intraday chart for Candel Therapeutics, Inc. +23.14% +395.92%
Jul. 01 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Completeness Index CI
Jul. 01 Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Completeness Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell 3000E Value Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Microcap Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000E Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2500 Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000E Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000 Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Dynamic Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Comp Growth Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2500 Index
CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000 Index
CI
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
GL
Candel Therapeutics to Join Russell 3000® Index
GL
Candel Therapeutics to Join Russell 3000® Index
AQ
Candel Therapeutics : Corporate Presentation - June 2024
PU
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
AQ
FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CADL Stock
  4. News Candel Therapeutics, Inc.